vs

Side-by-side financial comparison of American Express (AXP) and Connect Biopharma Holdings Ltd (CNTB). Click either name above to swap in a different company.

Connect Biopharma Holdings Ltd is the larger business by last-quarter revenue ($24.1M vs $18.9M, roughly 1.3× American Express). Connect Biopharma Holdings Ltd runs the higher net margin — 61.6% vs 15.7%, a 45.9% gap on every dollar of revenue.

American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...

Connect Biopharma Holdings Ltd is a clinical-stage global biopharmaceutical company dedicated to developing innovative targeted therapies for inflammatory, immunological and autoimmune diseases. Its core pipeline includes candidate treatments for asthma, atopic dermatitis and other conditions with high unmet medical needs, with main operations across the U.S., China and key global markets to deliver effective therapeutic solutions to patients.

AXP vs CNTB — Head-to-Head

Bigger by revenue
CNTB
CNTB
1.3× larger
CNTB
$24.1M
$18.9M
AXP
Higher net margin
CNTB
CNTB
45.9% more per $
CNTB
61.6%
15.7%
AXP

Income Statement — Q1 FY2026 vs Q2 FY2024

Metric
AXP
AXP
CNTB
CNTB
Revenue
$18.9M
$24.1M
Net Profit
$3.0M
$14.8M
Gross Margin
Operating Margin
56.6%
Net Margin
15.7%
61.6%
Revenue YoY
11.4%
Net Profit YoY
15.0%
148.7%
EPS (diluted)
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXP
AXP
CNTB
CNTB
Q1 26
$18.9M
Q4 25
$10.9B
Q3 25
$10.4B
Q2 25
$10.3B
Q1 25
$9.6B
Q4 24
$10.0B
Q3 24
$9.7B
Q2 24
$9.8B
$24.1M
Net Profit
AXP
AXP
CNTB
CNTB
Q1 26
$3.0M
Q4 25
$2.5B
Q3 25
$2.9B
Q2 25
$2.9B
Q1 25
$2.6B
Q4 24
$2.2B
Q3 24
$2.5B
Q2 24
$3.0B
$14.8M
Operating Margin
AXP
AXP
CNTB
CNTB
Q1 26
Q4 25
28.2%
Q3 25
36.7%
Q2 25
34.4%
Q1 25
34.6%
Q4 24
27.7%
Q3 24
33.0%
Q2 24
38.6%
56.6%
Net Margin
AXP
AXP
CNTB
CNTB
Q1 26
15.7%
Q4 25
22.5%
Q3 25
27.9%
Q2 25
28.0%
Q1 25
26.8%
Q4 24
21.8%
Q3 24
25.8%
Q2 24
30.7%
61.6%
EPS (diluted)
AXP
AXP
CNTB
CNTB
Q1 26
Q4 25
$3.52
Q3 25
$4.14
Q2 25
$4.08
Q1 25
$3.64
Q4 24
$3.04
Q3 24
$3.49
Q2 24
$4.15
$0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXP
AXP
CNTB
CNTB
Cash + ST InvestmentsLiquidity on hand
$110.2M
Total DebtLower is stronger
$60.4M
Stockholders' EquityBook value
$34.0M
$110.9M
Total Assets
$308.9M
$120.6M
Debt / EquityLower = less leverage
1.78×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXP
AXP
CNTB
CNTB
Q1 26
Q4 25
$742.0M
Q3 25
$1.3B
Q2 25
$197.0M
Q1 25
$261.0M
Q4 24
$221.0M
Q3 24
$120.0M
Q2 24
$188.0M
$110.2M
Total Debt
AXP
AXP
CNTB
CNTB
Q1 26
$60.4M
Q4 25
$56.4B
Q3 25
$57.8B
Q2 25
$58.2B
Q1 25
$51.2B
Q4 24
$49.7B
Q3 24
$53.5B
Q2 24
$51.5B
Stockholders' Equity
AXP
AXP
CNTB
CNTB
Q1 26
$34.0M
Q4 25
$33.5B
Q3 25
$32.4B
Q2 25
$32.3B
Q1 25
$31.2B
Q4 24
$30.3B
Q3 24
$29.7B
Q2 24
$29.5B
$110.9M
Total Assets
AXP
AXP
CNTB
CNTB
Q1 26
$308.9M
Q4 25
$300.1B
Q3 25
$297.6B
Q2 25
$295.6B
Q1 25
$282.2B
Q4 24
$271.5B
Q3 24
$271.0B
Q2 24
$272.2B
$120.6M
Debt / Equity
AXP
AXP
CNTB
CNTB
Q1 26
1.78×
Q4 25
1.68×
Q3 25
1.78×
Q2 25
1.80×
Q1 25
1.64×
Q4 24
1.64×
Q3 24
1.80×
Q2 24
1.74×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXP
AXP
CNTB
CNTB
Operating Cash FlowLast quarter
$-8.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.54×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXP
AXP
CNTB
CNTB
Q1 26
Q4 25
$3.1B
Q3 25
$6.2B
Q2 25
$4.4B
Q1 25
$4.8B
Q4 24
$5.8B
Q3 24
$-1.8B
Q2 24
$4.5B
$-8.0M
Free Cash Flow
AXP
AXP
CNTB
CNTB
Q1 26
Q4 25
$2.3B
Q3 25
$5.6B
Q2 25
$3.7B
Q1 25
$4.3B
Q4 24
$5.3B
Q3 24
$-2.3B
Q2 24
$4.0B
FCF Margin
AXP
AXP
CNTB
CNTB
Q1 26
Q4 25
21.4%
Q3 25
53.6%
Q2 25
36.3%
Q1 25
45.0%
Q4 24
53.1%
Q3 24
-23.3%
Q2 24
40.4%
Capex Intensity
AXP
AXP
CNTB
CNTB
Q1 26
Q4 25
6.6%
Q3 25
6.3%
Q2 25
6.0%
Q1 25
4.5%
Q4 24
5.0%
Q3 24
4.7%
Q2 24
5.8%
Cash Conversion
AXP
AXP
CNTB
CNTB
Q1 26
Q4 25
1.25×
Q3 25
2.15×
Q2 25
1.51×
Q1 25
1.84×
Q4 24
2.66×
Q3 24
-0.72×
Q2 24
1.50×
-0.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXP
AXP

Discount revenue$9.5M50%
Other$8.9M47%
Deposits with banks and other$512.0K3%

CNTB
CNTB

Segment breakdown not available.

Related Comparisons